We are live on ! Find out more
LC

Lindbrook Capital Portfolio holdings

AUM $1.08B
1-Year Est. Return 10.14%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+10.14%
3 Year Est. Return
+35.77%
5 Year Est. Return
+141.26%
10 Year Est. Return
AUM
$1.06B
AUM Growth
-$4.21M
Cap. Flow
-$36.2M
Cap. Flow %
-3.4%
Top 10 Hldgs %
45.51%
Holding
2,874
New
227
Increased
1,384
Reduced
630
Closed
115

Top Sells

Rank Stock Value
1
OCSL icon
Oaktree Specialty Lending
OCSL
+$12.7M
2
NVDA icon
NVIDIA
NVDA
+$6.29M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$3.66M
4
AAPL icon
Apple
AAPL
+$3.19M
5
AVGO icon
Broadcom
AVGO
+$2.17M

Sector Composition

Rank Sector Weight
1 Technology 17.21%
2 Financials 12.25%
3 Healthcare 6.29%
4 Communication Services 4.39%
5 Consumer Discretionary 3.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARQT icon
2176
Arcutis Biotherapeutics
ARQT
$3.3B
$3.32K ﹤0.01%
357
-125
-26% -$1.13K
CENX icon
2177
Century Aluminum
CENX
$5.18B
$3.32K ﹤0.01%
+198
New +$3.37K
RXT icon
2178
Rackspace Technology
RXT
$1.11B
$3.31K ﹤0.01%
1,111
-533
-32% -$1.07K
CWAN
2179
DELISTED
Clearwater Analytics
CWAN
$3.28K ﹤0.01%
+177
New +$3.19K
MATX icon
2180
Matsons
MATX
$6.11B
$3.27K ﹤0.01%
25
+11
+79% +$1.28K
BTSG icon
2181
BrightSpring Health Services
BTSG
$11.5B
$3.27K ﹤0.01%
288
BBIO icon
2182
BridgeBio Pharma
BBIO
$16.4B
$3.27K ﹤0.01%
129
-367
-74% -$10K
CTRE icon
2183
CareTrust REIT
CTRE
$9.14B
$3.26K ﹤0.01%
130
+7
+6% +$173
RARE icon
2184
Ultragenyx Pharmaceutical
RARE
$2.66B
$3.25K ﹤0.01%
79
-38
-32% -$1.62K
ATR icon
2185
AptarGroup
ATR
$8.57B
$3.24K ﹤0.01%
23
+13
+130% +$1.88K
ASB icon
2186
Associated Banc-Corp
ASB
$6.02B
$3.24K ﹤0.01%
153
+38
+33% +$800
LFST icon
2187
Lifestance Health
LFST
$4.39B
$3.24K ﹤0.01%
659
TARS icon
2188
Tarsus Pharmaceuticals
TARS
$3.05B
$3.23K ﹤0.01%
119
+25
+27% +$841
ACRE
2189
Ares Commercial Real Estate
ACRE
$262M
$3.23K ﹤0.01%
486
+301
+163% +$2.08K
HIFS icon
2190
Hingham Institution for Saving
HIFS
$685M
$3.22K ﹤0.01%
18
+10
+125% +$1.73K
FL
2191
DELISTED
Foot Locker
FL
$3.19K ﹤0.01%
128
-21
-14% -$500
XHR
2192
Xenia Hotels & Resorts
XHR
$1.72B
$3.18K ﹤0.01%
+222
New +$3.21K
ACHC icon
2193
Acadia Healthcare
ACHC
$2.9B
$3.17K ﹤0.01%
47
-21
-31% -$1.47K
SMBK icon
2194
SmartFinancial
SMBK
$887M
$3.17K ﹤0.01%
+134
New +$2.9K
COGT icon
2195
Cogent Biosciences
COGT
$6.61B
$3.17K ﹤0.01%
+376
New +$2.85K
ZYME icon
2196
Zymeworks
ZYME
$1.73B
$3.16K ﹤0.01%
371
+53
+17% +$472
SHAK icon
2197
Shake Shack
SHAK
$2.9B
$3.15K ﹤0.01%
35
-66
-65% -$6.44K
CHEF icon
2198
Chefs' Warehouse
CHEF
$4.46B
$3.13K ﹤0.01%
80
+19
+31% +$702
RAMP icon
2199
LiveRamp
RAMP
$2.3B
$3.13K ﹤0.01%
101
+11
+12% +$353
SEM
2200
DELISTED
Select Medical
SEM
$3.12K ﹤0.01%
165
+41
+33% +$699

Similar funds

Lindbrook Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Lindbrook Capital held 2,874 positions worth $1.06B, down 0.39% from $1.07B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Lindbrook Capital withdrew a net $36.2M in Q2 2024, closing 115 positions and reducing 630 holdings. Its most notable exit was ProShares UltraPro QQQ, an estimated $1.24M position sold in full.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Lindbrook Capital opened a new position in Nuveen ESG Small-Cap ETF worth $323K.

  • Lindbrook Capital's largest Q2 2024 buy was Nuveen ESG Small-Cap ETF: 8,216 shares worth $323K.
  • Lindbrook Capital added most to State Street SPDR S&P 500 ETF Trust in Q2 2024, an estimated $3.36M increase.
  • Lindbrook Capital's biggest Q2 2024 reduction was Oaktree Specialty Lending, cutting an estimated $12.7M.
  • Lindbrook Capital fully exited ProShares UltraPro QQQ in Q2 2024, selling an estimated $1.24M.
  • Lindbrook Capital's ten largest holdings make up 46% of its $1.06B portfolio in Q2 2024.
  • Lindbrook Capital opened 227 new positions and closed 115 in Q2 2024.
  • Lindbrook Capital's portfolio value fell 0.39% quarter-over-quarter to $1.06B.

Based on Lindbrook Capital's 13F filing for Q2 2024, filed 31 Jul 2024.